Primary central nervous system lymphomas

Current Treatment Options in Oncology

Volumn 2, Issue 4, 2001, Pages 309-318

  DeAngelis, Lisa M ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Main Drug Interaction; Main Side Effect; Ommaya Reservoir; Primary Central Nervous System Lymphoma; Primary Central Nervous System Lymphoma Patient

Indexed keywords

ANTICONVULSIVE AGENT; ANTINEOPLASTIC AGENT; CORTICOSTEROID; METHOTREXATE;

ADULT; AGED; B CELL LYMPHOMA; BIOPSY; BRAIN TUMOR; CANCER INVASION; CRANIOTOMY; DIAGNOSTIC IMAGING; DRUG CONTRAINDICATION; EYE; HUMAN; INTRASPINAL DRUG ADMINISTRATION; MENINX; METHODOLOGY; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; NONHODGKIN LYMPHOMA; PATHOLOGY; REVIEW; SEIZURE; SKULL IRRADIATION; STEREOTAXIC SURGERY; SURVIVAL; TREATMENT OUTCOME; VITRECTOMY;

ADRENAL CORTEX HORMONES; ADULT; AGED; ANTICONVULSANTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOPSY; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; CRANIAL IRRADIATION; CRANIOTOMY; DIAGNOSTIC IMAGING; EYE; HUMANS; INJECTIONS, SPINAL; LYMPHOMA, AIDS-RELATED; LYMPHOMA, NON-HODGKIN; MENINGES; METHOTREXATE; MIDDLE AGED; NEOPLASM INVASIVENESS; SEIZURES; STEREOTAXIC TECHNIQUES; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VITRECTOMY;

EID: 0035436429     PISSN: 15272729     EISSN: 15346277     Source Type: Journal    
DOI: 10.1007/s11864-001-0024-6     Document Type: Article

References (18)

1. DeAngelis LM, Yahalom J: Primary central nervous system lymphoma. In Principles and Practice of Oncology Updates. Edited by DeVita VT Jr, Hellman S, Rosenberg SA. Philadelphia: JB Lippincott; 1992:6:1–12.
2. Glantz MJ, Cole BF, Friedberg MH, et al.: A randomized, blinded, placebo-controlled trial of divalproex sodium prophylaxis in adults with newly diagnosed brain tumors. Neurology 1996, 46:985–991.
3. Weaver S, Forsyth P, Fulton D, et al.: A prospective randomized study of prophylactic anticonvulsants (AC) in patients with primary brain tumors (PBT) or metastatic brain tumors (MBT) and without prior seizures (Sz): a preliminary analysis of 67 patients [abstract]. Neurology 1995, 45:A263.
4. Ferreri AJM, Reni M, Villa E: Therapeutic management of primary central nervous system lymphoma: lessons from prospective trials. Ann Oncol 2000, 11:927–937. An excellent overview of current management and treatment. DOI: 10.1023/A:1008376412784
5. Reni M, Ferreri AJM, Garancini MP, et al.: Therapeutic management of primary central nervous system lymphoma in immunocompetent patients: results of a critical review of the literature. Ann Oncol 1997, 8:227–234. DOI: 10.1023/A:1008201717089
6. Abrey LA, DeAngelis LM, Yahalom J: Long-term survival in primary CNS lymphoma. J Clin Oncol 1998, 16:859–863. Prolonged survival is seen with high-dose methotrexate and cranial radiotherapy, but significant neurotoxicity can be seen with prolonged follow-up.
7. Abrey LE, Yahalom J, DeAngelis LM: Treatment for primary central nervous system lymphoma (PCNSL): the next step. J Clin Oncol 2000, 18:3144–3150. Chemotherapy alone is equally efficacious to chemotherapy plus radiotherapy in older patients and less toxic.
8. McAllister LD, Doolittle ND, Guastadisegni PE, et al.: Cognitive outcomes and long-term follow-up results after enhanced chemotherapy delivery for primary central nervous system lymphoma. Neurosurgery 2000, 46:51–60. DOI: 10.1097/00006123-200001000-00010
9. O’Neill BP, O’Fallon JR, Earle JD, et al.: Primary central nervous system non-Hodgkin’s lymphoma: survival advantages with combined initial therapy? Int J Radiat Oncology Biol Phys 1995, 33:663–673. DOI: 10.1016/0360-3016(95)00207-F
10. Mead GM, Bleehen NM, Gregor A, et al.: A medical research council randomized trial in patients with primary cerebral non-Hodgkin lymphoma. Cerebral radiotherapy with and without cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy. Cancer 2000, 89:1359–1370. This study finds that CHOP is ineffective for PCNSL. DOI: 10.1002/1097-0142(20000915)89:6<1359::AID-CNCR21>3.0.CO;2-9
11. Freilich RJ, Delattre J-Y, Monjour A, et al.: Chemotherapy without radiation therapy as initial treatment for primary CNS lymphoma in older patients. Neurology 1996, 46:435–439.
12. Sandor V, Stark-Vancs V, Pearson D, et al.: Phase II trial of chemotherapy alone for primary CNS and intraocular lymphoma. J Clin Oncol 1998, 16:3000–3006.
13. Nelson DF, Martz KL, Bonner H, et al.: Non-Hodgkin’s lymphoma of the brain: can high dose, large volume radiation therapy improve survival? Report on a prospective trail by the radiation therapy oncology group (RTOG): RTOG 8315. Int J Radiat Oncol Biol Phys 1992, 23:9–17.
14. Yu X, Liu Z, Tian Z, et al.: CT-guided stereotactic biopsy of deep brain lesions: report of 310 cases. Chin Med J (Engl) 1998, 111:361–363.
15. Kulkarni AV, Guha A, Lozano A, et al.: Incidence of silent hemorrhage and delayed deterioration after stereotactic brain biopsy. J Neurosurg 1998, 89:31–35. DOI: 10.3171/jns.1998.89.1.0031
16. Sandberg DI, Bilsky MH, Souweidane MM, et al.: Ommaya reservoirs for the treatment of leptomeningeal metastases. Neurosurgery 2000, 47:49–55. DOI: 10.1097/00006123-200007000-00011
17. Raizer JJ, DeAngelis LM, Zelentz AD, et al.: Activity of Rituximab in primary central nervous system lymphoma PCNSL. Proc ASCO 2000, 19:166a.
18. Reni M, Ferreri AJM, Landoni C, Villa E: Salvage therapy with temozolomide in an immunocompetent patient with primary brain lymphoma. J Natl Cancer Inst 2000, 92:575–576. DOI: 10.1093/jnci/92.7.575